http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference
-
Buyer Group International Provides Shareholder Update on Metallurgical Advancements and Permitting Momentum
-
Fobi AI Announces Extension of Non-Brokered Private Placement
-
Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference
-
Star Copper Congratulates Doubleview Gold's Mineral Resource Estimate Boosting Interest Across Entire Region
-
Golden Matrix Group Announces Reverse Stock Split and Name Change to Meridian Holdings
-
Trailbreaker Resources Announces Flow-Through Financing up to $3M
-
SOLIGENIX receives positive EMA opinion for SGX945 orphan drug designation
-
ImmunityBio completes enrollment in bladder cancer trial ahead of schedule
-
FreshBooks and Bluevine Partner to Help U.S. Small Business Owners Simplify Financial Management
-
Laramide to Update Westmoreland Economic Study
-
Beyond Minerals Announces LIFE Offering for up to $600,000 and Marketing Services Agreement
-
ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
-
Rio Silver Secures Community Permission to Commence Site Activities at Maria Norte, Peru
-
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease
-
Blackline Safety Announces Fiscal First Quarter 2026 Financial Results Conference Call
-
Victory Capital proposes $57.04 per share offer for Janus Henderson
-
Victory Capital Affirms Fully Financed, Clearly Superior Proposal to Acquire Janus Henderson
-
FDA accepts Ionis olezarsen application for priority review
-
FDA accepts Ionis' olezarsen application for priority review
-
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
-
Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)
-
Hilton Grand Vacations Reports Fourth Quarter and Full Year 2025 Results
-
KingKonree Expands ADA Sink Solutions to Support Inclusive Design Across North American Commercial Projects
-
BlackSky Reports Fourth Quarter and Full Year 2025 Results
-
Strengthening Europe's Supply Chain: Aurania Updates on Balangero Nickel-Cobalt Project
-
SAP Releases Integrated Report 2025 and Files Annual Report 2025 on Form 20-F with the U.S. Securities and Exchange Commission
-
DORITOS® LAUNCHES BOLDEST INNOVATION YET: DORITOS PROTEIN
-
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance
-
Isocyanate Market worth $39.68 billion by 2030 - Exclusive Report by MarketsandMarkets™
-
AIxC Hub Surpasses 4.8M Registered Wallets, Introduces New Season, and Announces "Agentir" for AI Agents
-
Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics
-
Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics
-
Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results
-
SolCex Enters Major Expansion Phase Following Two Years of Secure, Continuous Operation
-
Wealth Minerals closes final tranche of private placement for $546,000
-
Wealth Minerals Closes Final Tranche of Private Placement
-
AIAA Bids to Bring the World’s Premier Space Event to the United States in 2029
-
DaluoSEO.com Awarded Top 10 SEO Agency for AI SaaS Companies in 2026
-
GFG Grants Stock Options and Announces Upcoming Investor Conferences
-
Xanadu and Mitsubishi Chemical Make Breakthrough Quantum Algorithms for Next-Generation Semiconductor Manufacturing
-
FDA approves Merck's NUMELVI for dog skin allergies
-
FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Alle
-
NANOBIOTIX to Participate in Investor Conferences in March
-
NANOBIOTIX to Participate in Investor Conferences in March
-
Lightbridge Provides Business Update and Announces Fiscal Year 2025 Financial Results
-
IMAX Corporation Reports Fourth Quarter and Full Year 2025 Results
-
Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results
-
Korro to Present at the TD Cowen 46th Annual Health Care Conference
-
Arrcus to Showcase Industry’s First AI Inference Network Fabric at MWC Barcelona
